Titan Pharmaceuticals

TTNP65

Penny Stock

$4.75arrow_drop_down2.68%-$0.12

Penny Stock

TTNP65

$4.75

arrow_drop_down2.68%-$0.12

Penny Stock

Performance History

Key Stats
Open	$4.70
Prev. Close	$4.70
EPS	-6.50
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$4.45M
PE Ratio	-

	LOW	HIGH
Day Range	4.60	4.84
52 Week Range	4.24	14.80

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-6.50

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Titan Pharmaceuticals (TTNP)

Titan Pharmaceuticals Inc (TTNP) is a pharmaceutical company that specializes in developing and commercializing therapeutics for the treatment of chronic diseases. The company's main focus is on developing long-term, implantable drug delivery systems for patients suffering from addiction and chronic pain. These innovative technologies aim to provide patients with a more convenient and effective way of receiving medication, while also improving treatment outcomes. With a strong pipeline of product candidates and a commitment to research and development, Titan Pharmaceuticals is well-positioned to make a positive impact on the lives of patients worldwide.

One of the key factors to consider when evaluating Titan Pharmaceuticals Inc is its stock price history. By analyzing the historical price movements of the stock, investors can gain insights into the company's performance over time. It is important to note that stock prices are influenced by various factors, including market conditions, industry trends, and company-specific news. Therefore, a comprehensive analysis of these factors is necessary to understand the stock's potential for future growth.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. David Elliot Lazar
Headquarters: South San Francisco
Employees: 4
Exchange: NASDAQ

Keep an eye on Titan Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Titan Pharmaceuticals (TTNP)?

Titan Pharmaceuticals (TTNP) has a market capitalization of $4.3M. The average daily trading volume is 4.73, indicating the stock's liquidity and investor engagement.

help

What is Titan Pharmaceuticals 's (TTNP) price per share?

The current price per share for Titan Pharmaceuticals (TTNP) is $4.75. The stock has seen a price change of -$0.13 recently, indicating a -2.69% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Titan Pharmaceuticals (TTNP)?

For Titan Pharmaceuticals (TTNP), the 52-week high is $14.8, which is 211.57% from the current price. The 52-week low is $4.24, the current price is 12.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Titan Pharmaceuticals (TTNP) a growth stock?

Titan Pharmaceuticals (TTNP) has shown an average price growth of -1.93% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Titan Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Titan Pharmaceuticals (TTNP) stock price performance year to date (YTD)?

As of the latest data, Titan Pharmaceuticals (TTNP) has a year-to-date price change of -42.42%. Over the past month, the stock has experienced a price change of -17.68%. Over the last three months, the change has been -8.65%. Over the past six months, the figure is -33.1%. Looking at a longer horizon, the five-year price change stands at -95.6%.

help

Is Titan Pharmaceuticals (TTNP) a profitable company?

Titan Pharmaceuticals (TTNP) has a net income of -$5.57M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 39.13% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -237.63K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $72K. Operating income is noted at -$7.28M. Furthermore, the EBITDA is -$7.09M.